TCR2 Therapeutics Inc. (TCRR)

Business: TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.

IPO Date: 14-Feb-2019

Pres, CEO & Director: Dr. Garry E. Menzel M.B.A., Ph.D.

Founder & Member of the Advisory Board: Dr. Patrick A. Baeuerle Ph.D.

Listing: NASDAQ: TCRR

Country: United States

Headquarters: Cambridge, MA

Website: https://www.tcr2.com

Market cap: $112.17 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-107.42 Mln

Cash: $232.19 Mln

Total Debt: $53.68 Mln

Insider's Holding: 0.89%

Liquidity: Low

52 Week range: $2.07 - 19.03

Shares outstanding: 38,546,300

6 Years Aggregate:

• CFO: $-219.90 Mln
• EBITDA: $-262.95 Mln
• Net Profit: $-261.77 Mln